Full Year 2022 Oxford Biomedica PLC Earnings Call Transcript
So hello, everyone, and thank you for joining our meeting today, our analyst report meeting -- on the results of 2022. I'm Frank Mathias. I'm the newly appointed Chief Executive Officer of the company. And believe me, it's a great pleasure to meet you today together with our Chief Financial Officer, Stuart Paynter. I believe you are known here.
So just for those who do not know me by now, I'm French, as you can hear from my accent, I'm sure about that. I was born in Paris, and I went to school there and to the university. So I'm pharmacist by education with a PhD in immunology and more than 30 years now of experience in the biopharmaceutical environment in senior positions at different companies throughout the biopharmaceutical industry. As you might know, I come from another renowned CDMO, namely Rentschler Biopharma, where I was CEO for about 7 years.
So also, I have only started 3 weeks ago. To be very precise, 3 weeks, 1.5 days ago. I can already say the following, and this is in line with what I have expected from the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |